Test Price
2,800 AED✅ Home Collection Available
NKX3-2 Gene Spondylo-Megaepiphyseal-Metaphyseal Dysplasia Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
- Premium Logistics: VIP mobile phlebotomy & temperature-controlled cold-chain home collection (daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic post-test counselling by a consultant medical geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
- Specimen: Whole blood, extracted DNA, or FTA card drop – no fasting required.
- Turnaround: 3–4 weeks from sample receipt.
- Method: Ultra-deep NGS with CNV detection, validated per ISO 9001:2015 (INT/EGQ/2509DA/3139).
- DHA Licensed: Facility License 1143, DNA Labs UAE, Dubai Healthcare City.
Test Overview & Methodology
This advanced NGS test detects pathogenic variants in the NKX3-2 gene, providing definitive molecular diagnosis for Spondylo-megaepiphyseal-metaphyseal dysplasia (SMMD) – a rare skeletal disorder. The entire coding region and splice sites are sequenced with ultra-deep coverage, enabling detection of point mutations, small insertions/deletions, and copy number variations (CNVs).
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | NGS with 99.9% analytical sensitivity & specificity | Sanger sequencing (limited to known single variants) |
| Method | Ultra-deep NGS, CNV detection, validated per ISO 9001:2015 | PCR-based panels or exome sequencing without focused gene coverage |
| Speed | 3–4 weeks from sample receipt | 6–8 weeks typical |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that this test detects pathogenic variants, but a positive result must be correlated with radiological and clinical findings. A negative result does not exclude the diagnosis if clinical suspicion remains high. Always combine genetic data with expert phenotyping and family history.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA 9294403
Medication & Safety Advisory
Important Safety Information
Do not discontinue any prescribed medication without consulting your doctor. This test is diagnostic and does not replace ongoing medical management.
Exclusion Criteria & Emergency Red Flags
- Individuals with known anaphylaxis to blood draw supplies – refer to facility for alternative collection methods.
- Active severe infection or hemodynamic instability – stabilise before sample collection.
- Seek emergency care if you experience: sudden severe bone pain, joint dislocation, or respiratory distress.
- Children under 18 must be accompanied by a legal guardian per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of NKX3-2 gene testing?
Snippet: NKX3-2 NGS testing confirms the molecular diagnosis of Spondylo-megaepiphyseal-metaphyseal dysplasia, enabling precise management, genetic counseling, and family screening.
The test sequences the entire coding region of the NKX3-2 gene using next-generation sequencing, detecting point mutations, small insertions/deletions, and copy number variations with high accuracy.
2. How should I prepare for the sample collection?
Snippet: No fasting is required; simply provide a blood sample (whole blood, extracted DNA, or a drop on FTA card) after a genetic counselling session to document family history.
Our home collection team arranges a convenient time; a clinical history form and pedigree chart will be completed to enhance interpretation.
3. How accurate is this test compared to other methods?
Snippet: It delivers 99.9% analytical sensitivity and specificity, outperforming single-gene Sanger sequencing by capturing the full NKX3-2 coding region with deep coverage.
The laboratory holds ISO 9001:2015 certification (INT/EGQ/2509DA/3139), ensuring robust quality management and reproducible results.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
- All genetic data is handled in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical testing and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- The laboratory is licensed by the Dubai Health Authority (DHA) under facility license number 1143.
- Results are released only to the ordering physician or directly to the patient upon verified consent.
Clinical & Logistical Metadata
| Test Name | NKX3-2 Gene Spondylo-Megaepiphyseal-Metaphyseal Dysplasia Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card drop |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV detection |
| ICD-10-CM Code | Q77.8 (Other osteochondrodysplasia) |
| LOINC Code | 93268-5 (NKX3-2 gene targeted mutation analysis) |
| DHA Facility License & Laboratory Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians